Core Viewpoint - As of June 24, 2023, AAPG's stock price increased by 4.17%, reaching $38.7 per share, with a total market capitalization of $3.372 billion. The company reported a total revenue of 981 million RMB for the year ending December 31, 2024, representing a year-on-year growth of 341.77%, while the net profit attributable to shareholders was -405 million RMB, showing a growth of 56.2% year-on-year [1][2]. Company Overview - AAPG is a biopharmaceutical company based in China, focusing on global markets, dedicated to developing innovative drugs for the treatment of cancer, hepatitis B, and age-related diseases [2]. - The company was listed on the Hong Kong Stock Exchange on October 28, 2019, under the stock code 6855.HK [2]. - AAPG has developed a proprietary drug design platform targeting protein-protein interactions and is at the forefront of new drug development in the apoptosis pathway [2]. Product Pipeline - The company has established a pipeline of nine Class 1 small molecule new drugs that have entered clinical development, including inhibitors targeting key proteins in the apoptosis pathway such as Bcl-2, IAP, and MDM2-p53 [2]. - AAPG is the only innovative company globally with clinical development products in all key proteins of the apoptosis pathway [2]. - The core product, Aorebatin (brand name: Nairike), has been approved in China and included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2022) [2]. Clinical Trials and Regulatory Approvals - The company is conducting over 40 clinical trials across China, the United States, Australia, and Europe [2]. - AAPG has received multiple designations from the FDA, including Fast Track designation, Orphan Drug designation, and two designations for pediatric rare diseases [2]. Research and Development - AAPG has undertaken several national science and technology major projects, including five under the "Major New Drug Creation" initiative [2]. - The company has established global collaborations with leading biotech and pharmaceutical companies and academic institutions, enhancing its research capabilities [2]. - AAPG is committed to improving its R&D capabilities and accelerating the clinical development of its product pipeline to meet unmet clinical needs globally [2].
亚盛医药上涨4.17%，报38.7美元/股，总市值33.72亿美元